LAVA Therapeutics appoints KPMG as new auditor, dismisses PwC

LAVA Therapeutics NV

Board approved KPMG as independent auditor for FY2025, dismissing PwC effective May 20, 2025.
PwC's reports for FY2023 and FY2024 were unqualified, with no adverse opinions or modifications.
No accounting disagreements with PwC; prior material weaknesses in IT controls and segregation of duties were remediated as of Dec 31, 2024.
PwC's letter agreeing with the statements is filed as Exhibit 16.1.

item 4.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.